Free Shipping for order over $49 within the U.S.

Lifeflower® & Lifeflower® Plus

Lifeflower® supports brain & cerebrovascular health.

Product Details

BRE-002 Lifeflower® Breviscapine (Scutellarin ≥98%, HPLC)

BRE-003 Lifeflower® Breviscapine (Scutellarin ≥90%, HPLC)

Molecular Formula: C12H18O12

Molecular Weight: 462.36

CAS#: 116122-36-2

Chemical Nature: Dietary Ingredient

Common Name: Erigeron Breviscapus Extract, Scutellarin, Breviscapinum

Quality Control Seed-to-Sale Traceability

  • GAP Cultivation
  • cGMP Manufacturing
  • GSP Logistic & Warehousing
  • Independent Verify Quality
  • FDA Compliance

Related Studies

Wang, WW et al. "Scutellarin May Alleviate Cognitive Deficits In A Mouse Model Of Hypoxia By Promoting Proliferation And Neuronal Differentiation Of Neural Stem Cells.". Iran J Basic Med Sci 20.3 (2017): 272-279.

Zhong, Haijun et al. "Multivesicular Liposome Formulation For The Sustained Delivery Of Breviscapine". International Journal of Pharmaceutics 301.1-2 (2005): 15-24.

Xia, Qing-jie et al. "Breviscapine Reduces Neuronal Injury Caused By Traumatic Brain Injury Insult: Partly Associated With Suppression Of Interleukin-6 Expression" Neural Regeneration Research 12.1 (2017): 90.

Pengyue, Zhang et al. "Breviscapine Confers A Neuroprotective Efficacy Against Transient Focal Cerebral Ischemia By Attenuating Neuronal And Astrocytic Autophagy In The Penumbra". Biomedicine & Pharmacotherapy 90 (2017): 69-76.

Yiming, Liu et al. "Neuroprotective Effects Of Breviscapine Against Apoptosis Induced By Transient Focal Cerebral ischaemia In Rats". Journal of Pharmacy and Pharmacology 60.3 (2008): 349-355.

Wang, Wenjuan et al. "Neuroprotective Effect Of Scutellarin On Ischemic Cerebral Injury By Down-Regulating The Expression Of Angiotensin-Converting Enzyme And ATI Receptor". PLOS ONE 11.1 (2016): e0146197.

Following Test Report Available Upon Request

Jing Ma  2017a.  A Single Dose Toxicity Study of Breviscapine for Injection in Sprague Dawley Rats via Intravenous Injection.  Study No. 1610AD1.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  May 23, 2018, pp. 64. 

Jing Ma  2017b.  The toxicity test data and literature for rats with repeated administration.  The toxicity test on SD rats receiving 4-week repeated intravenous injection with breviscapine injection in 4-week recovery period.  Study No. 1016RD1.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  June 28, 2018, summary of test results, pp. 4. 

Jing Ma  2017c.  The toxicity test data and literature for Beagle dogs with repeated administration.  The toxicity test on Beagle dogs receiving 4-week repeated intravenous injection with breviscapine injection in the 4-week recovery period.  Study No. 1016RD2.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  June 28, 2018, summary of test results, pp. 3. 

Jing Ma  2017d.  Test data and literature for anaphylactic (systemic) special safety.  Active systemic anaphylaxis test for guinea pigs with the administration of breviscapine injection.  Study No. 1610HY2.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  June 4, 2018, summary of test results, pp. 3. 

Jing Ma  2017e.  Test data and literature for the special safety of hemolysis.  Hemolysis test for the breviscapine injection.  Study No. 1610HL1.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  May 14, 2018, summary of test results, pp. 2. 

Jing Ma  2017f.  The toxicity test data and literature for rats with repeated administration.  The toxicity test on SD rats receiving 4-week repeated intravenous injection with breviscapineinjection in 4-week recovery period with micronucleus test.  Study No. 1016RD1.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  June 28, 2018, summary of test results, pp. 4. 

Jing Ma  2017g.  Test data and literature of genetic toxicity.  Bacterial reverse mutation test for the breviscapine injection.  Study No. 1610AM1.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  April 19, 2018, summary of test results, pp. 2. 

Jing Ma  2017h.  Genetic toxicity test data and literature.  The micronucleus test on SD rats receiving intravenous injection with breviscapine injection.  The accompanied toxicity test on SD rats receiving 4-week repeated intravenous injection with breviscapine injection in 4-week recovery period.  Study No. 1610RD1.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  June 28, 2018, summary of test results, pp. 2. 

Jing Ma  2017i.  Test data and literature of genetic toxicity.  The chromosome aberration test on Chinese hamster lung fibroblast cell line for the breviscapine injection.  Study No. 1016CA1.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  April 9, 2018, summary of test results, pp. 3. 

Jing Ma  2017j.  Test data and literature for genetic toxicity.  The comet assay on SD rats receiving the intravenous injection with breviscapine injection.  Study No. 1610CO1.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  July 6, 2018, summary of test results, pp. 3. 

Jing Ma  2017k.  Test data and literature for reproductive toxicity.  The toxicity test of reproduction and early embryonic development for SD rats receiving the intravenous injection with breviscapine injection.  Study No. 1610RA1.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  March 14, 2018, summary of test results, pp. 3. 

Jing Ma  2017l.  Test data and literature for special safety of local irritation.  The irritation test on administration sites of Beagle dogs receiving intravenous injection with breviscapine injection.  The accompanied toxicity test on Beagle dogs receiving 4-week repeated intravenous injection with breviscapine injection in 4-week recovery period.  Study No. 1016RD2.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  March 14, 2018, summary of test results, pp. 2. 

Jing Ma  2017m.  Test data and literature for anaphylactic (systemic) special safety.  The passive cutaneous anaphylaxis test for rats receiving the breviscapine injection.  Study No. 1016HY4.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  June 4, 2018, summary of test results, pp. 3. 

Order Now

To order our raw materials, call us at 1-888-327-5664, e-mail us at social@farlong.com or fill out the form below.